In this report, “GBT,” “Company,” “we,” “our,” and “us” means Global Blood Therapeutics, Inc., and/or one or more of our subsidiaries, unless the context otherwise provides.
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On March 24, 2022, Willie L. Brown, Jr., resigned, effective immediately, from the Board of Directors, or Board, of Global Blood Therapeutics, Inc., and the Board’s Nominating and Corporate Governance Committee. His resignation was not a result of any disagreement with the Company. Mr. Brown will continue his affiliation with the Company as a director emeritus, serving as an advisor to the Company.
On March 24, 2022, solely in order to provide for an equal apportionment of the members of the Board among the three classes of the Company’s classified Board following Mr. Brown’s resignation as described above, Alexis A. Thompson, M.D., M.P.H., resigned from the Board as a Class I director, effective immediately, and was immediately reappointed by the remaining members of the Board as a Class II director, to serve in such capacity until the next annual meeting of stockholders at which the term of the Class II directors expires or until her successor is duly elected and qualified, or her earlier death, resignation or removal. With such change, Classes I, II and III each have three directors. Because Dr. Thompson’s resignation and reappointment were effected solely to maintain the size of each class as nearly equal in number as possible, her service on the Board is deemed to have continued uninterrupted without any break in service.
In addition, on March 24, 2022, the Board approved a reduction in the size of Class I from four members to three, and of the size of the Board from ten to nine members, effective concurrently with the changes in the composition of the Board described above.
